Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Protein Kinase C Epsilon Type - Pipeline Review, H2 2018'; Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules.
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine%li%and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.
The report 'Protein Kinase C Epsilon Type - Pipeline Review, H2 2018' outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Ophthalmology which include indications Alzheimer's Disease, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alcohol Addiction, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Ischemic Stroke, Neurology, Rett Syndrome and Traumatic Brain Injury.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Protein Kinase C Epsilon Type - Pipeline Review, H2 2018'; Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules.
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine%li%and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.
The report 'Protein Kinase C Epsilon Type - Pipeline Review, H2 2018' outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Ophthalmology which include indications Alzheimer's Disease, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alcohol Addiction, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Ischemic Stroke, Neurology, Rett Syndrome and Traumatic Brain Injury.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
- The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
CHS Pharma Inc
Neurotrope Bioscience Inc
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
Bryostatin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulindac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Sep 26, 2018: Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer’s Disease (CTAD2018)
Jul 25, 2018: At AAIC 2018, Neurotrope presents additional clinical results showing cognitive improvement in phase 2 data assessing Bryostatin-1 in moderate-to-severe alzheimer’s patients
Jul 16, 2018: Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer’s Disease
Jul 01, 2018: Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting
May 07, 2018: Neurotrope In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimers Patients
Jan 05, 2018: Neurotropes Bryostatin Improves Cognition in Patients with Advanced Alzheimers Disease Based on Further Analysis of Phase 2 Clinical Trial Data
Dec 19, 2017: Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease
Jul 19, 2017: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017
Jun 29, 2017: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting
May 01, 2017: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
Apr 28, 2017: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017
Feb 28, 2017: Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia
Nov 22, 2016: Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease
Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead
Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
CHS Pharma Inc
Neurotrope Bioscience Inc
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
Bryostatin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulindac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Sep 26, 2018: Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer’s Disease (CTAD2018)
Jul 25, 2018: At AAIC 2018, Neurotrope presents additional clinical results showing cognitive improvement in phase 2 data assessing Bryostatin-1 in moderate-to-severe alzheimer’s patients
Jul 16, 2018: Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer’s Disease
Jul 01, 2018: Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting
May 07, 2018: Neurotrope In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimers Patients
Jan 05, 2018: Neurotropes Bryostatin Improves Cognition in Patients with Advanced Alzheimers Disease Based on Further Analysis of Phase 2 Clinical Trial Data
Dec 19, 2017: Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease
Jul 19, 2017: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017
Jun 29, 2017: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting
May 01, 2017: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease
Apr 28, 2017: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017
Feb 28, 2017: Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia
Nov 22, 2016: Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease
Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead
Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by CHS Pharma Inc, H2 2018
Pipeline by Neurotrope Bioscience Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by CHS Pharma Inc, H2 2018
Pipeline by Neurotrope Bioscience Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
COMPANIES MENTIONED
CHS Pharma Inc
Neurotrope Bioscience Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
COMPANIES MENTIONED
CHS Pharma Inc
Neurotrope Bioscience Inc
